将CTLA-4/PD-1阻断疗法纳入宫颈癌治疗：COMPASSION-16研究结果
Integrating CTLA-4/PD-1 blockade into cervical cancer management: Results of COMPASSION-16.
作者信息
How Jeffrey A, Jazaeri Amir A
机构信息
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Med. 2025 Jan 10;6(1):100558. doi: 10.1016/j.medj.2024.11.011.
Abstract
Although there is anti-tumor efficacy of dual CTLA-4/PD-1 blockade in advanced/recurrent cervical cancer, it is unclear whether combination with chemotherapy is synergistic. In COMPASSION-16, Wu et al. demonstrated improved survival outcomes of cadolinimab plus chemotherapy compared to chemotherapy alone for first-line systemic therapy for advanced/recurrent cervical cancer, suggesting a potential role of bispecific CTLA-4/PD-1 inhibitors in the frontline setting..
摘要
尽管双重CTLA-4/PD-1阻断在晚期/复发性宫颈癌中具有抗肿瘤疗效，但尚不清楚与化疗联合是否具有协同作用。在COMPASSION-16研究中，Wu等人证明，对于晚期/复发性宫颈癌的一线全身治疗，卡多利单抗联合化疗的生存结果优于单纯化疗，这表明双特异性CTLA-4/PD-1抑制剂在一线治疗中具有潜在作用。
相似文献
1
Integrating CTLA-4/PD-1 blockade into cervical cancer management: Results of COMPASSION-16.将CTLA-4/PD-1阻断疗法纳入宫颈癌治疗：COMPASSION-16研究结果
Med. 2025 Jan 10;6(1):100558. doi: 10.1016/j.medj.2024.11.011.
2
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.巴替利单抗和泽利鲁单抗联合双 PD-1 和 CTLA-4 检查点阻断作为晚期宫颈癌二线治疗的开放标签 II 期研究。
J Clin Oncol. 2022 Mar 1;40(7):762-771. doi: 10.1200/JCO.21.02067. Epub 2021 Dec 21.
3
Cadonilimab plus chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer: a cost-effectiveness analysis.卡度尼利单抗联合化疗作为持续性、复发性或转移性宫颈癌的一线治疗：一项成本效益分析
Front Immunol. 2025 Apr 3;16:1562875. doi: 10.3389/fimmu.2025.1562875. eCollection 2025.
4
Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.巴司替利单抗及其他用于复发性和转移性宫颈癌的免疫疗法。
Med Oncol. 2022 Jan 29;39(4):47. doi: 10.1007/s12032-022-01646-7.
5
Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial.卡度尼利单抗（PD-1/CTLA-4双特异性抗体）联合化疗治疗抗PD-1耐药的复发或转移性鼻咽癌的疗效和安全性：一项单臂、开放标签的2期试验
BMC Med. 2025 Mar 11;23(1):152. doi: 10.1186/s12916-025-03985-4.
6
Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study.在晚期实体瘤患者中使用 CS1002 和 CS1003（nofazinlimab）进行双重 CTLA-4 和 PD-1 检查点阻断：一项首次人体、剂量递增和剂量扩展研究。
Cancer. 2024 Jun 1;130(11):1991-2002. doi: 10.1002/cncr.35226. Epub 2024 Feb 26.
7
Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.晚期宫颈癌的基因组分析预测程序性死亡受体-1 抑制剂联合治疗的反应：CLAP 试验的二次分析。
J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2020-002223.
8
First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions.一线免疫检查点抑制剂治疗晚期非小细胞肺癌：现状与未来方向。
Drugs. 2020 Nov;80(17):1783-1797. doi: 10.1007/s40265-020-01409-6.
9
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.卡度尼利单抗（一种抗 PD-1/CTLA-4 双特异性抗体）治疗晚期实体瘤患者的安全性和抗肿瘤活性（COMPASSION-03）：一项多中心、开放标签、Ib/II 期试验。
Lancet Oncol. 2023 Oct;24(10):1134-1146. doi: 10.1016/S1470-2045(23)00411-4.
10
Combination of cadonilimab (PD-1/CTLA-4 bispecific antibody) and apatinib as salvage therapy achieves partial response in MSI-H advanced gastric cancer: a case report.卡度尼利单抗（PD-1/CTLA-4双特异性抗体）联合阿帕替尼作为挽救治疗在微卫星高度不稳定（MSI-H）晚期胃癌中取得部分缓解：一例病例报告
Front Immunol. 2025 Feb 18;16:1533700. doi: 10.3389/fimmu.2025.1533700. eCollection 2025.
引用本文的文献
1
Unlocking the potential of immune checkpoint inhibitors in advanced cervical cancer: a meta-analysis and systematic review.揭示免疫检查点抑制剂在晚期宫颈癌中的潜力：一项荟萃分析与系统评价
BMC Cancer. 2025 May 13;25(1):863. doi: 10.1186/s12885-025-14264-z.
本文引用的文献
1
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.卡度尼利单抗联合含铂化疗±贝伐珠单抗作为持续性、复发性或转移性宫颈癌一线治疗（COMPASSION-16）：中国一项随机、双盲、安慰剂对照的 3 期临床试验。
Lancet. 2024 Oct 26;404(10463):1668-1676. doi: 10.1016/S0140-6736(24)02135-4. Epub 2024 Oct 16.
2
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.纳武利尤单抗联合或不联合伊匹木单抗治疗复发性或转移性宫颈癌患者（CheckMate 358）：一项1/2期、开放标签、多队列试验
Lancet Oncol. 2024 May;25(5):588-602. doi: 10.1016/S1470-2045(24)00088-3. Epub 2024 Apr 9.
3
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
4
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study.卡度尼利单抗联合化疗±贝伐珠单抗作为复发性或转移性宫颈癌一线治疗的研究（COMPASSION-13）：一项2期研究
Clin Cancer Res. 2024 Apr 15;30(8):1501-1508. doi: 10.1158/1078-0432.CCR-23-3162.
5
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.一线帕博利珠单抗+化疗对比安慰剂+化疗用于持续性、复发性或转移性宫颈癌：KEYNOTE-826 的最终总生存结果。
J Clin Oncol. 2023 Dec 20;41(36):5505-5511. doi: 10.1200/JCO.23.00914. Epub 2023 Nov 1.
6
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.巴替利单抗和泽利鲁单抗联合双 PD-1 和 CTLA-4 检查点阻断作为晚期宫颈癌二线治疗的开放标签 II 期研究。
J Clin Oncol. 2022 Mar 1;40(7):762-771. doi: 10.1200/JCO.21.02067. Epub 2021 Dec 21.
7
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.派姆单抗治疗持续性、复发性或转移性宫颈癌。
N Engl J Med. 2021 Nov 11;385(20):1856-1867. doi: 10.1056/NEJMoa2112435. Epub 2021 Sep 18.
8
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).贝伐珠单抗治疗晚期宫颈癌：一项随机、对照、开放标签、3 期临床试验（妇科肿瘤学组 240）的最终总生存和不良事件分析。
Lancet. 2017 Oct 7;390(10103):1654-1663. doi: 10.1016/S0140-6736(17)31607-0. Epub 2017 Jul 27.
9
Improved survival with bevacizumab in advanced cervical cancer.贝伐珠单抗治疗晚期宫颈癌可提高生存率。
N Engl J Med. 2014 Feb 20;370(8):734-43. doi: 10.1056/NEJMoa1309748.
Zotero 插件